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Abstract
Background: Polymorphism in the FTO gene is strongly associated with obesity, but little is
known about the molecular bases of this relationship. We investigated whether hypothalamic FTO
is involved in energy-dependent overconsumption of food. We determined FTO mRNA levels in
rodent models of short- and long-term intake of palatable fat or sugar, deprivation, diet-induced
increase in body weight, baseline preference for fat versus sugar as well as in same-weight animals
differing in the inherent propensity to eat calories especially upon availability of diverse diets, using
quantitative PCR. FTO gene expression was also studied in organotypic hypothalamic cultures
treated with anorexigenic amino acid, leucine. In situ hybridization (ISH) was utilized to study FTO
signal in reward- and hunger-related sites, colocalization with anorexigenic oxytocin, and c-Fos
immunoreactivity in FTO cells at initiation and termination of a meal.
Results: Deprivation upregulated FTO mRNA, while leucine downregulated it. Consumption of
palatable diets or macronutrient preference did not affect FTO expression. However, the
propensity to ingest more energy without an effect on body weight was associated with lower FTO
mRNA levels. We found that 4-fold higher number of FTO cells displayed c-Fos at meal termination
as compared to initiation in the paraventricular and arcuate nuclei of re-fed mice. Moreover, ISH
showed that FTO is present mainly in hunger-related sites and it shows a high degree of
colocalization with anorexigenic oxytocin.
Conclusion: We conclude that FTO mRNA is present mainly in sites related to hunger/satiation
control; changes in hypothalamic FTO expression are associated with cues related to energy intake
rather than feeding reward. In line with that, neurons involved in feeding termination express FTO.
Interestingly, baseline FTO expression appears linked not only with energy intake but also energy
metabolism.
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Background
Human studies show a strong association of a single
nucleotide polymorphism in the FTO gene with obesity
and diabetes in diverse ethnic groups [1-7]. Common
intronic variants in this gene have been linked with
increased body weight and adiposity [8]; e.g., individuals
homozygous for the rs9939609 allele, weigh ~3 kg more
than those with low-risk alleles [3]. High-risk variants
carry a population-attributable likelihood of overweight
and obesity exceeding 20% [3,6]. Aside from the associa-
tion with BMI, variations in the FTO gene have been
linked with glucose metabolism [1,9], type 2 diabetes
[10,11], distribution of subcutaneous fat and amount of
liver fat, as well as non-visceral and visceral adipose tissue
[12]. FTO codes for 2-oxoglutarate-dependent nucleic
acid demethylase that likely plays a role in oxidative
demethylation of 3-methylthymine and 3-methyluracil in
single-stranded DNA and RNA [13].
Little is known about the nature of the association
between FTO and BMI; only a few basic research studies
have been performed on laboratory animals. Fontanesi et
al. found that FTO is associated with intermuscular fat
deposition in pigs [14]. FTO mRNA is present in many tis-
sue types, but its most abundant expression was detected
in the brain, particularly, in hypothalamic nuclei which
govern feeding [15,16]. In rodents, starvation modifies
FTO mRNA levels detected with real-time PCR (rtPCR) in
the entire hypothalamus and in the arcuate nucleus
(ARC), however both up- and downregulation have been
shown, thus, FTO expression alterations may be depend-
ent on the severity of starvation or other factors
[16,17,15]. These changes are independent from leptin
[16]. Generation of the knock-out (KO) model was a cru-
cial step in understanding FTO's role in body weight con-
trol. KO mice displayed decreased body weight despite
consuming more standard chow than wild type (WT) con-
trols; this effect persisted from post-natal day 2 onwards.
In addition, FTO mRNA was found to colocalize with ARC
proopiomelanocortin (POMC) [18], which gives rise to,
among others, a satiety factor alpha-melanocyte stimulat-
ing hormone and reward mediating beta-endorphin.
Animal experiments performed to date have not
addressed the key issue of whether FTO's involvement in
weight gain is based solely on energy-related mechanisms
or there is also a reward component. The current project
was designed to characterize the relationship between
FTO and obesity through feeding models, molecular anal-
yses and functional neuroanatomy in mice. Special atten-
tion was given to the hypothalamus as - aside from
primarily regulating energy intake - it mediates feeding
reward [19,20].
We investigated whether FTO mRNA levels respond to a
brief fast. Since overeating, especially of palatable tastants,
serves as an obesogenic factor, we studied the effect of
short-term (48 h) overconsumption of sucrose or fat on
hypothalamic FTO expression. We examined whether
body weight increase induced by long-term exposure to
sugar has any effect. Furthermore, individual preferences
for fat versus sucrose were correlated to the baseline FTO
expression. Since same-weight mice exhibited inherent
differences in their propensity to consume energy espe-
cially when diverse diets were offered, we compared the
baseline expression profiles in individuals that ate more
to the ones that ingested fewer calories and we employed
a similar rat model to confirm our findings. Organotypic
cultures of the hypothalamus were used to study FTO
mRNA levels following the addition of a satiating amino
acid, leucine [21].
We performed in situ hybridization (ISH) to compare
FTO expression in strictly reward-related sites to that in
the hypothalamus, a region involved in both feeding for
energy and reward [19,20]. As FTO was found to coexpress
with POMC, double ISH-immunohistochemistry (IHC)
was performed to determine whether FTO colocalizes
with another hypothalamic feeding regulator, the anorex-
igenic peptide, oxytocin [22,23]. Finally, using IHC detec-
tion of an immediate-early gene product, c-Fos, we
studied activity of FTO neurons at initiation vs. termina-
tion of feeding.
Methods
Animals
Male C57BL/6J mice (Scanbur, Sweden) were housed
individually or in groups of two (PCR Exp. 1, 2 and 3) in
macrolon cages with LD 12:12 (lights on at 0700). The
animals were 12 weeks old and they weighed ca. 28 g at
the beginning of the experiment. Water and chow
(Lactamin, Sweden) were available ad libitum unless
noted otherwise. Procedures described herein received a
prior approval from the Uppsala Animal Welfare Com-
mittee.
Rt-PCR studies
Experiment 1. Hypothalamic FTO expression following 16-h 
deprivation
Food was removed just before the onset of darkness and
mice (n = 8) were decapitated between 1000 and 1100 on
the next day. The controls (n = 8) had food ad libitum.
Experiment 2. Hypothalamic FTO expression following 48-h 
consumption of palatable sucrose or Intralipid
Mice were given a bottle of 10% sucrose or 4.1% Intralipid
in addition to chow for 48 h; controls had chow only (n =
8/group). Intralipid (Fresenius, Sweden), a palatable lipid
emulsion of soybean oil, glycerol and egg yolk phosphol-
ipids, has been used in experiments utilizing liquid diets
[24,25]. Sucrose and Intralipid were isocaloric (0.4 kcal/
g), whereas the energy content of chow was 3.6 kcal/g. TheBMC Neuroscience 2009, 10:129 http://www.biomedcentral.com/1471-2202/10/129
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solutions were similar in palatability: each mouse
ingested on average 8.1 kcal of Intralipid and 7.4 kcal of
sucrose daily. Total caloric intake per mouse was 10.3 kcal
in the chow group, 14.1 kcal in the sucrose group and
12.9 kcal in the Intralipid group. Mice were decapitated
after 48 h (between 1100 and 1200).
Experiment 3. Hypothalamic FTO expression upon increased body 
weight
Mice were given 10% sucrose in addition to chow for 3
weeks; controls had chow only (n = 8/group). The initial
body weights did not differ (controls: 27.6 ± 0.3 g;
sucrose: 27.8 ± 0.5 g). After 3 weeks of chow and sucrose
intake, mice weighed 32.1 ± 0.4 g, whereas the chow con-
trols weighed 29.5 ± 0.6 g (P < 0.05; t-test). Energy intake
was similar to that described for the corresponding groups
in Exp. 1. Mice were decapitated after 3 weeks (1100-
1200).
Experiment 4. Hypothalamic FTO expression in mice differing in 
preference for sugar vs. fat
Mice were given 10% sucrose and 4.1% Intralipid in addi-
tion to chow for 7 days. During the first two days, animals
got accustomed to tastants. Subsequently, according to
the standards applied in previous reports [26,27], the
mice were divided based on the 5-day preference profile:
1) sucrose-preferring (n = 7), 57.0 ± 2.2% of sucrose +
Intralipid calories came from sucrose; (2) fat-preferring (n
= 7), 39.2 ± 3.0% calories came from sucrose; and (3) neu-
tral (n = 7), sucrose was the source of 46.9 ± 1.9% calories.
Sucrose and Intralipid were later removed and only chow
was given for 21 days ("washout") so that gene expression
levels at endpoint were not affected by consumption of
palatable tastants. The animals were decapitated (1100-
1200). Body weights at the end of the palatable tastant
availability and at the end of the "washout" phase did not
differ between the preference groups.
Experiment 5. Hypothalamic FTO expression in mice differing in 
calorie intake upon availability of a diverse diet
The set-up in Exp. 4 provided a diverse diet that included
standard chow, palatable sucrose and Intralipid. Although
animals displayed different propensities to ingest sucrose
and Intralipid, some of them - regardless of preference -
ingested overall (sucrose+Intralipid+chow) more energy
than others. The "small eaters" (n = 10) ate daily 11.3 ±
0.4 kcal of all tastants while the "big eaters" (n = 11), 14.4
± 1.2 kcal (P < 0.05; t-test). The difference in the amount
of consumed food was significant in the environment rich
in diverse foods. The initial body weight did not differ
between the groups ("small eaters": 27.2 ± 0.4 g; "big eat-
ers": 27.5 ± 0.3 g). The 7-day exposure to palatable diets
did not induce changes in body weight (29.0 ± 0.4 g and
28.3 ± 0.3 g, respectively; P = 0.287). Once palatable liq-
uids were removed and the animals had only access to
chow for 21 days, energy intake did not differ between
groups during this "washout phase" although a slight
trend remained (cumulative intake for big eaters: 241.8 ±
14.1 kcal vs small eaters: 221 ± 12.6 kcal; P = 0.160) and
neither did body weights (P = 0.605) at decapitation.
Experiment 6. Arcuate hypothalamic FTO expression in rats that 
differ in calorie intake upon availability of a diverse diet
This experiment was included to examine whether the
FTO expression pattern in the "big/small eaters" paradigm
can be detected in rats. Male Wistar rats, housed individu-
ally with free access to chow and water, received for 10
days a 30% sucrose solution (n = 10), a bowl of lard (n =
10), or both tastants (n = 15). Animals increased their
caloric intake when presented with the palatable diets
(229 ± 3.4 kcal/kg on chow and 276 ± 5.7 kcal/kg on pal-
atable diets; P < 0.0001). The animals were divided into
"big eaters" (n = 17) and "small eaters" (n = 17): 249 ± 3.0
kcal/kg for the "small eaters" and 302 ± 5.9 kcal/kg for the
"big eaters". Body weights did not differ between the
groups following the exposure to palatable diets or at end-
point (P = 0.411 and 0.640, respectively). Arcuate hypoth-
alamic FTO expression was studied with rtPCR.
Experiment 7: FTO expression in organotypic cultures of the 
hypothalamus treated with anorexigenic leucine
Organotypic hypothalamic slice cultures were prepared as
previously described [28]. Briefly, 21-day-old male
C57BL6 mice were decapitated, the brains were removed
under sterile conditions and transferred to the Gey's Bal-
anced Salt Solution (GBSS) (Biological Industries, Israel)
containing 25 mM glucose. Hypothalami were dissected
and sliced into 300-μm thick sections using the McIlwian
tissue chopper. Slices from each brain were placed sepa-
rately on semiporous membranes (Millipore) inserted
into six-well culture plates (Sarstedt) containing 1.2 ml of
the serum-Opti-MEM medium in each well. Culture
medium was a mixture of Opti-MEM (50%; Gibco), horse
serum (25%) and Hanks' Balanced Salt Solution (HBSS)
(25%; Gibco) supplemented with 50% D(+) glucose
monohydrate (25 mM, Merc). Growing medium of the
experimental group (n = 7) was supplemented with 0.3 μg
leucine; controls (n = 7) had no leucine added. The
amount of supplemented leucine was based on the previ-
ous report utilizing central administration of this amino
acid to reduce food intake [21]. Cultures were maintained
at 37°C in a humidified atmosphere of 5% CO2. Medium
was changed daily. After 48 h FTO expression was studied
with rtPCR.
PCR
Brains were excised, hypothalami dissected, immersed in
RNAlater (Ambion, USA), kept at room temperature for 2
h and, thereafter, stored at -80°C until further processed.
Samples were homogenized and RNA prepared as previ-
ously described [15,29] [see Additional file 1].BMC Neuroscience 2009, 10:129 http://www.biomedcentral.com/1471-2202/10/129
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RT-PCR
Relative expression levels of 6 housekeeping genes
(HKGs) and genes of interest were determined with quan-
titative rtPCR. Each reaction, with a total volume of 20 μl,
contained 20 mM Tris/HCl, 50 mM KCl, 4 mM MgCl2, 0.2
mM dNTP, DMSO (1:20) and SYBR Green (1:50000).
Template concentration was 5 ng/μl and the concentra-
tion of each primer was 2 pmol/μl. Primers were designed
with Beacon Designer (Premier Biosoft) using the SYBR
Green settings. Sequences are presented in Additional file
1. All rtPCR experiments were performed in duplicates; a
negative control for each primer pair and a positive con-
trol with 5 ng/μl of genomic DNA were included on each
plate. Amplifications were performed with 0.02 μ/ml Taq
DNA polymerase (Biotools, Sweden) under the following
conditions: initial denaturation at 95°C for 3 min, 50
cycles of denaturing at 95°C for 15 sec, annealing at 52.8-
60.1°C for 15 sec and extension at 72°C for 30 sec.
Data analysis and relative expression calculations
Analysis of rtPCR data was performed as previously
reported [29]. MyIQ 1.0 software (Bio-Rad) was used.
Primer efficiencies were calculated using LinRegPCR [30]
and samples were corrected for differences in primer effi-
ciencies. The GeNorm protocol described by Vandesom-
pele et al. [31] was used to calculate normalization factors
from the expression levels of the HKGs. Grubbs' test was
used to remove outliers (6 outliers were removed)
[32,33]. Differences in gene expression between groups
were analyzed with ANOVA followed by Fisher's PLSD
test where appropriate. P < 0.05 was used as the criterion
of statistical significance.
ISH detection of FTO in sites involved in hunger versus 
reward
Four mice were anaesthetized with pentobarbital and per-
fused with 5 ml 0.9% NaCl followed by 50 ml 4% para-
formaldehyde in 0.1 M phosphate buffer. Perfusions took
place between 1100 and 1200. The brains were immersed
in the same fixative overnight at 4°C. Coronal sections
were cut at 50 μm with a Vibratome and processed as free-
floating sections.
The FTO cDNA clone was obtained from Invitrogen. Plas-
mid DNA preparation was done with the JETstar 2.0 Plas-
mid Purification Midi Kit/50 (Genomed, Germany). The
clones were sequenced (MWG, Germany) and confirmed
to contain 773 bp of the 3' UTR of the mouse FTO tran-
script. 20 μg of plasmid DNA was lineraized by digestion
with 30 U SpeI (Fermentas, Latvia) for 3 h. Ribo probes
were synthesized using 1 μg template, RiboLock Ribonu-
clease Inhibitor (Fermentas, Sweden) and 40 U RNA
polymerases in the presence of digoxigenin-11-UTP
(Roche). Probe quantification was performed with a Nan-
oDrop ND-1000 Spectrophotometer (NanoDrop Tech-
nologies). The synthesis of the FTO RNA probe was
performed according to the previously described protocol
[15]. FTO mRNA was detected in the tissue as described
before [15] and the full protocol can be found in Addi-
tional file 1. Evaluation of FTO expression was based on
the visual inspection; the following scale was applied: 0,
not detectable; +, weak; ++, moderate; +++, high. Every
other section was used for the ISH.
Detection of oxytocin in FTO neurons
Following the completion of the ISH procedure, every
other PVN section was used in the IHC staining to detect
oxytocin. Sections were rinsed in TBS, incubated in 3%
H2O2/10% methanol for 10 min. The tissue was incu-
bated 24 h in the rabbit-anti-oxytocin antibody (1:15000;
Chemicon), followed by incubations in the goat-anti-rab-
bit (1:400; Vector Laboratories) and avidin-biotin com-
plex (1:800; Vector Laboratories) for 1 h. Peroxidase in the
tissue was visualized with 0.05% diaminobenzidine and
0.01% H2O2 was used to catalyze the reaction. Rinsing
steps were done with TBS. The vehicle for antibody incu-
bations was 0.25% gelatin and 0.5% Triton X-100 in TBS.
Sections were analyzed visually and the percentage of oxy-
tocin neurons colocalizing with FTO was determined.
Detection of c-Fos in FTO neurons at feeding initiation and 
termination
Mice (n = 10) were food-deprived for 16 h. Chow was
returned at 1000. Deprivation-induced meal was com-
pleted within ~30 min (each mouse ingested 2.0-2.4 g
chow). Five mice were perfused at the time corresponding
to the initiation of feeding, whereas the other five at the
time corresponding to the termination of consumption.
Since the maximum c-Fos IR occurs 1 h after the onset of
neuronal activity [34], animals were perfused 1 h after
food presentation (initiation)or 1 h after meal comple-
tion (termination).
The ISH protocol was as described above. In IHC, the
modifications included the use of the goat-anti-Fos
(1:1500; Santa Cruz) and rabbit-anti-goat (1:400; Vector
Laboratories) antibody. The percentage of Fos-positive
FTO in the PVN and ARC was determined and values were
compared with Student's t-test (significant when P <
0.05).
Results
Exposure to palatable, isocaloric sucrose or Intralipid for
48 h did not affect FTO expression (Fig. 1a); the animals
had the same body weight. When mice were given 3-week
access to sugar, which caused a greater body weight
increase than intake of chow alone (32.1 ± 0.4 g and 29.5
± 0.6 g, respectively; P < 0.05), FTO mRNA levels were still
the same in both groups (Fig. 1b). Also animals that had
distinct preference profiles for sugar vs. fat did not differBMC Neuroscience 2009, 10:129 http://www.biomedcentral.com/1471-2202/10/129
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in the baseline FTO expression (Fig. 1d). In the three
aforementioned models, changes in expression of other
reference genes known for their involvement in food
intake control could be detected. Those included kappa
(KOR) and mu (MOR) opioid receptors, dynorphin
(DYN), proopiomelanocortin (POMC), melanocortin
receptor-4 (MC4R) and melanin concentrating hormone
(MCH).
In contrast, FTO expression was increased in deprived ani-
mals (Fig. 1f). Treating organotypic cultures of the
hypothalamus with anorexigenic leucine caused downreg-
ulation of FTO mRNA as well as of two orexigenic genes,
NPY and ORX (Fig. 1c). Finally, the propensity to eat less
during the exposure to a self-composed, diverse and pal-
atable diet was associated with higher FTO mRNA levels.
During the exposure, "small eaters" ate fewer calories than
"big eaters" did (11.3 ± 0.4 kcal and 14.4 ± 1.2 kcal per
day, respectively; P < 0.05) and, after the 3-week "wash-
out" phase of chow intake (trend of elevated calorie intake
in big eaters; P = 0.160), they had ~50% higher FTO
mRNA content (P = 0.004; Fig. 1e). There was no change
in expression of several reference genes, including DYN,
POMC, neuropeptide Y (NPY), Agouti-related protein
Relative expression of FTO and feeding-related genes in the hypothalamus of mice Figure 1
Relative expression of FTO and feeding-related genes in the hypothalamus of mice. A. Mice were exposed for 48 
h to palatable Intralipid or sucrose solutions in addition to chow (n = 8/group). B. Mice differed in body weight by ca. 2.6 g. 
Increased body weight was induced by 3-week exposure to the sucrose solution given in addition to chow (n = 8/group). C. 
Organotypic cultures of the hypothalamus were treated for 48 h with anorexigenic leucine versus untreated controls (n = 7/
group). D. Mice differed in 5-day preference for fat (Intralipid) vs. sucrose (n = 7 per preference-based group). E. Mice differed 
in their propensity to ingest more calories during exposure to palatable diets ("big eaters", vs. "small eaters"; n = 11 and 10, 
respectively). A similar rat model was used as control of FTO expression in another species (FTO rat). F. Mice were deprived 
of food for 16 h preceding decapitation (n = 8/group). AGRP, Agouti-related protein; DYN, dynorphin; MC4R, melanocortin 
receptor-4; NPY, neuropeptide Y; ORX, orexin; POMC, proopiomelanocortin; KOR, kappa opioid receptor; MOR mu recep-
tor; MCH, melanin concentrating hormone. * - P < 0.05; ** - P < 0.01.BMC Neuroscience 2009, 10:129 http://www.biomedcentral.com/1471-2202/10/129
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(AGRP) and MC4R (Fig. 1e). Applying a similar paradigm
in rats resulted in the same outcome for the FTO mRNA in
the hypothalamic ARC, i.e. "small eaters" had an elevated
level of FTO (P = 0.030; Fig. 1e).
ISH detection of FTO mRNA revealed expression prima-
rily in the hypothalamus. Some sites linked with reward,
such as the ventral tegmental area (VTA) and nucleus
accumbens (Acb), had very little or lacked the FTO signal,
whereas others, e.g., the bed nucleus of the stria terminalis
and parabrachial nucleus, expressed moderate levels of
FTO (Table 1; Fig. 2). Double ISH-IHC analysis showed
that FTO mRNA is present in many neurons synthesizing
the anorexigenic peptide, oxytocin: 55 ± 6.1% oxytocin
neurons in the magnocellular subdivision of the PVN and
32 ± 5.8% in the parvocellular portion colocalized with
FTO (Fig. 3). Interestingly, we found that approximately
four times more FTO expressing cells in the PVN and ARC
display c-Fos (they are "active") at the time corresponding
to termination than to initiation of consummatory activ-
ity (Fig. 4). There was no difference between the two
groups in the number of FTO cells (data not shown).
Discussion
Consuming excessive amounts of foods, which serves as
the main factor in the development of obesity (and may
result in diabetes), is driven by either a perceived need to
acquire calories (eating for energy in response to the hun-
gry state) or hedonic aspects of eating (eating for pleasure)
or the combination of both. Our data strongly suggest that
FTO, the first gene contributing to common forms of
human obesity [8,35], plays a significant role in mecha-
nisms responsible for the regulation of energy-related eat-
ing behavior.
This presumed involvement in hunger control is reflected
by the neuroanatomical distribution of FTO visualized
through ISH. This gene is scarcely expressed within the
reward network: particularly low levels are found in the
Acb and VTA which host, e.g., opioid and dopaminergic
circuitry [36-39] mediating hedonics of food intake. On
the other hand, very high expression was detected in
hypothalamic regions, including the PVN, ARC and dor-
somedial nucleus (DMH) that encompass key genes influ-
encing hunger and satiety, such as NPY, AGRP, POMC
and MC4R.
Distribution primarily outside the "reward network" does
not exclude a possibility of this gene's involvement in
reward processes, especially since the molecular compo-
nents of the reward system (e.g. genes encoding opioid
peptides and receptors) are dispersed throughout the CNS
and present also in the hypothalamus [20]. In fact, intake
of palatable diets, especially those containing fat or sugar,
modifies expression of reward-related genes in the
hypothalamus; and reward mediators, e.g., opioid lig-
ands, injected in this structure are particularly effective in
changing intake of such foods [40-42]. However, in our
experiments we have not found evidence linking hypoth-
alamic FTO with feeding reward. Ingestion of palatable
sugar or fat did not affect FTO expression, which suggests
that FTO mRNA levels do not change upon exposure to
palatable tastants in general and there is no special rela-
tionship between FTO and a particular palatable macro-
nutrient (fat or sugar). This was seen following short- (48
h) and long-term (3 weeks) intake of rewarding tastants.
The outcome is in line with our previous findings showing
the lack of correlation in expression of FTO and reward-
related genes, including DYN and enkephalin, in rat dep-
rivation models [15]. In addition, differences in animals'
liking of sugar versus fat did not reflect any disparities in
FTO gene activity profile. It suggests that the inherent pref-
erence for a specific macronutrient is not dependent on
the baseline FTO expression in the hypothalamus. These
data are of particular importance as they suggest that
hypothalamic FTO's role is unrelated to eating for pleas-
ure or inclination to choose one palatable macronutrient
over another. As the mice maintained on sucrose for 3
weeks gained more weight than chow-fed controls, it also
indicates that the development of overeating-driven obes-
ity is not a causative factor in changes in FTO expression.
Table 1: Graded denotation of FTO expression in sites involved 
in reward-related consumption (regular font) vs. in those that 
regulate primarily energy intake (bold).
Area Expression
Nucleus accumbens shell +
Nucleus accumbens core 0
Ventral tegmental area 0
Parabrachial nucleus +
Bed nucleus of the stria terminalis +++
Supraoptic nucleus +++
Paraventricular nucleus ++
Dorsomedial nucleus ++
Ventromedial nucleus +++
Arcuate nucleus +++
Lateral hypothalamus +
Other sites: septohypothalamic nucleus, ++, lateral preoptic area, 0; 
suprachiasmatic nucleus, +++; locus coeruleus, ++.
Expression based on the visual inspection: 0, not detectable; +, weak; 
++, moderate; +++, high.BMC Neuroscience 2009, 10:129 http://www.biomedcentral.com/1471-2202/10/129
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ISH detection of FTO mRNA in sites involved in the regulation of energy- or reward-related feeding Figure 2
ISH detection of FTO mRNA in sites involved in the regulation of energy- or reward-related feeding. Panels A-
D show sites affecting mainly reward, whereas panels E and F depict energy-related areas. aca, anterior commisure; AcbC, 
nucleus accumbens core; AcbSh, Acb shell; ARC, arcuate nucleus; BST, bed nucleus of the stria terminalis; BSTMA, BST medial 
anterior; BSTMPL, BST medial posterolateral; DMH, dorsomedial nucleus; f, fornix; fr, fasciculus retroflexus; LC, locus core-
lueus; LH, lateral hypothalamus; LPO, lateral preoptic area; LV, lateral ventricle; ml, medial lemniscus; otr, optic tract; PBN, 
parabrachial nucleus; PVN, paraventricular nucleus; SHy, septohypothalamic nucleus; SCN, suprachiasmatic nucleus; scp, supe-
rior cerebellar peduncle; SON, supraoptic nucleus; VMH, ventromedial nucleus; VTA, ventral tegmental area; 3v, 3rd ventricle; 
4v, 4th ventricle; 7n, facial nerve. Scale bar: 0.4 mm (A, B) 0.5 mm (C-F).BMC Neuroscience 2009, 10:129 http://www.biomedcentral.com/1471-2202/10/129
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Colocalization of FTO and oxytocin Figure 3
Colocalization of FTO and oxytocin. Oxytocin (brown cells) and FTO mRNA (blue cells) detected in the coronal section 
containing the PVN. Thin arrows, neurons expressing oxytocin and FTO; Open arrows, oxytocin cells devoid of FTO. Scale 
bar: 0.25 mm. Inserts: three-fold higher magnification of PVN neurons of interest.BMC Neuroscience 2009, 10:129 http://www.biomedcentral.com/1471-2202/10/129
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This lack of change in FTO expression in the aforemen-
tioned models shows a striking difference from the
response of other feeding-related "reference" genes stud-
ied herein, including opioids, melanocortins and MCH.
Obviously, one cannot rule out the possibility that FTO
outside the hypothalamus may affect or be affected by the
feeding variables considered herein, including reward and
preference, but hypothalamic FTO shows a strong associ-
ation only with energy intake control.
Three independent studies have shown that depriving
rodents of food influences FTO mRNA content in the
brain [15-17]. In mice, fasting was reported to decrease
expression of this gene, however, starvation applied in
those studies was severe as it lasted 40-48 h [16,17].
Upregulation has been detected in rats. In the current
study, a short-term, overnight fast, upregulated FTO
mRNA. The data confirm that FTO is sensitive to a current
energy status of the organism, probably in terms of both
energy acquired and stored; but the results also point to
the necessity of defining parameters accompanying depri-
vation of various magnitudes and timeframes that shape
the FTO gene activity.
The Fos experiment showed that >4 times more FTO neu-
rons in the PVN and ARC were "activated" at feeding ter-
mination than initiation. Activity of FTO expressing cells
at the end of a meal suggests FTO's involvement in feeding
inhibitory mechanisms. In fact, c-Fos IR is increased in the
PVN and ARC of rodents following 1-h intake of caloric
but not non-caloric tastants [43]. Furthermore, an upward
trend in neuronal activity in hypothalamic cells synthesiz-
ing anorexigenic peptides has been reported: a greater per-
centage of Fos-positive neurons synthesizing oxytocin and
alpha-melanocyte stimulating hormone can be detected
at feeding termination [44,45]. Noteworthy, FTO is
expressed in PVN neurons that produce oxytocin, which is
released within the CNS in response to such satiation cues
Fos-IR FTO neurons in the PVN and ARC at initiation and termination of feeding Figure 4
Fos-IR FTO neurons in the PVN and ARC at initiation and termination of feeding. c-Fos was detected by IHC, 
whereas FTO mRNA by ISH. A. Percentage of Fos-positive FTO cells in the PVN and ARC. B and C. Coronal sections of mice 
perfused at the beginning and at the end of a meal. Thin arrows, Fos-positive nuclei, thick solid arrows, Fos-positive FTO cells, 
open arrows, FTO neurons devoid of Fos. Scale bar: 0.02 mm. D. Schematic representation of distribution of Fos-positive FTO 
cells (each blue point indicates one such cell) in the representative sections encompassing the PVN and ARC. dc, dorsal cap; 
lm, lateral magnocellular; mm, medial magnocellular; mp, medial parvocellular.BMC Neuroscience 2009, 10:129 http://www.biomedcentral.com/1471-2202/10/129
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as increased stomach distention and high plasma osmola-
lity. This colocalization occurs in magno- and parvocellu-
lar cells, which implies that FTO may influence the activity
of oxytocin neurons that project to the posterior pituitary
(magnocellular) as well as to sites linked with feeding
control, including the nucleus of the solitary tract and dor-
sal motor nucleus of the vagus (parvocellular) [46]. Our
oxytocin colocalization results along with the previous
report regarding POMC [18] indicate that FTO may be
involved in mechanisms that end consummatory activity,
thus, those that are closely tied with meal size (therefore,
amount of ingested energy) control. A previously reported
correlation in the expression of FTO and energy-related
gene encoding galanin-like peptide supports this concept
[15].
The question remained as to whether the role of FTO in
satiety-related hypothalamic neurons, such as those posi-
tive for POMC or oxytocin, is to increase or decrease their
activity. Addition of leucine, which in vivo reduces feed-
ing and activates anorexigenic neurons synthesizing
POMC [21], to hypothalamic organotypic cultures pro-
duced downregulation of FTO expression. This suggests
that nutrient cues mediating satiation decrease FTO
mRNA levels while increasing activity of the satiety net-
work (e.g., POMC cells), hence, there is the inverse rela-
tionship between FTO and satiety.
The first studies with the use of the FTO KO murine model
showed that the role of FTO in energy intake and metab-
olism regulation goes beyond short-term control of feed-
ing. Surprisingly, FTO KO mice weigh less even though
they exhibit relative hyperphagia [18]. Our "big/small eat-
ers" experiment further supports the findings obtained in
the KO mice. This experiment was inspired by the obser-
vations that diversity of foods propels energy intake
beyond levels required to satisfy energy needs. Interest-
ingly, under such conditions, some individuals display a
significantly higher degree of hyperphagia than others
[19,45]. The "big eaters" - characterized by lower FTO
expression (P = 0.004) - weighed the same as the "small
eaters", even though during the several-day diverse food
exposure period they ingested ca. 22% more energy and a
slight trend of higher energy intake (P = 0.160) remained
throughout the subsequent exposure to regular chow. Our
data indicate that the higher energy intake that does not
translate to increased body weight may be accompanied
by downregulation of the FTO gene in the hypothalamus.
This is in concert with the conclusion reached in the FTO
KO mouse studies that not only feeding, but also energy
metabolism and expenditure are affected by FTO.
Conclusion
Changes in hypothalamic FTO mRNA levels are associ-
ated with a deprived state as well as with the presence of
the amino acid leucine that promotes satiety and feeding
termination. In addition, c-Fos IR of FTO neurons in the
ARC and PVN increases at the end of consummatory activ-
ity; and FTO co-localizes with anorexigenic oxytocin in
the PVN. It allows us to speculate that hypothalamic FTO
may be involved in the regulation of energy intake, possi-
bly by affecting feeding termination mechanisms. Distri-
bution of FTO mRNA mainly in hunger/satiation-related
sites and lack of changes in FTO expression upon exposure
to palatable tastants call into question a possible involve-
ment of FTO in the reward component of feeding. Finally,
the inherent propensity to eat more without a change in
body weight is associated with low hypothalamic FTO
mRNA levels. In contrast, long-term palatability-driven
overconsumption (irrespective of the aforementioned
individual propensity to eat different amounts of food)
that leads to increase in body weight does not affect FTO
expression in the hypothalamus.
Overall, our molecular and histological data strongly link
hypothalamic FTO with the regulation of feeding for cal-
ories not for reward; the molecular analyses also point to
a possible role of this gene in energy metabolism.
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